Ontology highlight
ABSTRACT:
SUBMITTER: Lupfert C
PROVIDER: S-EPMC6310869 | biostudies-other | 2018 Dec
REPOSITORIES: biostudies-other
Lüpfert Christian C Dyroff Martin M von Richter Oliver O Gallemann Dieter D El Bawab Samer S Dolgos Hugues H Jung Don D Hecht Stefan S Johne Andreas A
CPT: pharmacometrics & systems pharmacology 20181031 12
Evofosfamide is a cytotoxic small-molecule prodrug preferentially activated under hypoxic conditions. The cytotoxicity of evofosfamide impacted the generation of in vitro drug-drug interaction (DDI) data, especially in vitro induction results. Therefore, a novel physiologically based pharmacokinetic (PBPK) approach was used, which involved available in vitro and clinical data of evofosfamide and combined it with induction data from the prototypical cytochrome P450 (CYP)3A inducer rifampicin. The ...[more]